Prana candidate reduces Abeta levels
Prana research shows PBT2 reduces Abeta and improves cognition in mouse model
- 10 July, 2008 16:11
- Comments
Key findings from Prana Biotechnology's [ASX: PBT] preclinical research of its proprietary PBT2 Alzheimer's drug have been published in the prestigious scientific journal Neuron.
The article, "Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxyquinoline analogs is associated with decreased interstitial Abeta," can be viewed on-line by Neuron subscribers.
PBT2 was found to rapidly and profoundly improve cognition in transgenic mice, by substantially reducing the amount of Abeta - amyloid beta, the main constituent of Alzheimer's plaques - in the brain over a nine-month period.
The findings will be presented at the 11th International Conference on Alzheimer's Disease, to be held in Chicago at the end of the month.
More about: Prana Biotechnology, PRANA BIOTECHNOLOGY
Books
-
Fluorescence Applications in Biotechnology and Life Sciences
-
Molecular Forensics
-
An Introduction to Molecular Biotechnology - Molecular Fundamentals, Methods and Applications in Modern Biotechnology
-
Proteins - Structure and Function
-
Dictionary of DNA and Genome Technology 2E
-
Molecular & Cell Biology for Dummies
-
Statistics for Terrified Biologists
-
The Scientific American a Day in the Life of Your Brain
-
Writing Scientific Research Articles - Strategy and Steps
Comments
Post new comment